Fig. 1: Seropositivity and neutralizing antibody levels induced by the bivalent and quadrivalent vaccines. | npj Vaccines

Fig. 1: Seropositivity and neutralizing antibody levels induced by the bivalent and quadrivalent vaccines.

From: Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines

Fig. 1: Seropositivity and neutralizing antibody levels induced by the bivalent and quadrivalent vaccines.

a Percentage of vaccine recipients with neutralizing antibody titers of >40 to vaccine HPV types ((6)/16/18 and non-vaccine HPV types (6)/31/33/45/52/58). Bars indicate boundaries of 95% confidence interval (CI). Sera of quadrivalent (Gardasil, 6/11/16/18) and bivalent (Cervarix, 16/18) vaccine recipients are shown in blue and orange columns, respectively. b Neutralizing peak (Month 7) antibody levels (Geometric mean titer, GMT) in neutralization-positive samples. The gray dots represent the EC50 values of one serum. Serum concentrations inhibiting 50% of the PsV infection (EC50 values) were calculated from median of triplicates.

Back to article page